Nucleic Acid Aptamer Selection Against Endoglin (CD105) for Marker of Overproduction of Endothelial Cells

Here is the link to my final manuscript: https://docs.google.com/document/d/1DRo2m--Hr9V4lYq8MnboE8rvMq-Y5Hyni1zN0zEZ2GU/edit

Proposal: https://docs.google.com/document/d/1kBQJ-g00D5QQ3sC3XXkGz-pPoDAdWXKPS34uYDIXR3A/edit?hl=en_US

Progress report 10/18/11: http://aptamerstream.blogspot.com/2011/10/r50-selection-against-cd105endoglin.html#links

Elena Mora

Figure 1: The role of endoglin in (TGF)-β adapted from Seon, Ben. (Seon Labs)

Cell-surface glycoprotein endoglin (CD105) has been identified as a promising marker for proliferation of human endothelial cells. These tumor-associated cells are optimal targets in therapeutic approaches for human cancer and identifying over-expressed cells (1). They may lead to a deeper understanding in angiogenesis and the use of anti-CD105 as a therapeutic agent (2). Aptamers also would be much more affordable than the antibody therapeutics currently available.
Specific Aim: Several components of the receptor complex Transforming Growth Factor (TGF)-β superfamily, and CD105, are shown to strongly bind together in these cells (3). Studies have also shown that inhibition of CD105 expression enhanced the TGF- β ability to suppress growth of cultured endothelial cells (3). In this respect, an aptamer could possibly serve a likewise function to suppress growth and spreading of malignant tumors.
An aptamer selected against CD105 would be useful in diagnosis and treatment of cancer tumors. Identification with this marker and possibly inhibiting the growth of these destructive cells could potentially be a powerful step towards more curative measures.

Elena Mora

Raybiotech_Catalog: 228-10388-2, Size: 10µg, Price: $ 189.00
(1) Lastres P, Letamendia A, Zhang H, Rius C., Almendro N: Endoglin modulates cellular response to TGF- β (2) Gougos A, Letarte M: Primary structure of endoglin, an RGd-containing glycoprotein endothelial cells (3) Li C, Hampson IN, Kumar P, Bernabeu C, Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor β on human vascular endothelial cells

9 comments:

Elena said...

Sorry I'm not sure why some of it is highlighted. I've been trying to fix it for the past 45 minutes...

Gwen Stovall said...

Hi Elena,
I've heard others had problems with the font too. Try using a completely different font. And - if that doesn't work, then talk to your mentor Michael, who can work with you to correct this problem.

Thank you,
Gwen Stovall

Gwen Stovall said...

Hi Elena,
I went ahead & fixed your formatting issues. I copied your text into notepad & then copied that into the blog. I then had to change the color of the text to white & that seemed to fix it.

Hope this helps!
Gwen

Elena said...

Thanks so much! :)

Santiago Diaz said...

Looks promising! Good job

Alec Rezigh said...

Nice idea! Your abstract is very concise. For others like me, I might suggest providing a little more background about both the CD105 and the associated therapeutic protein. Also, don't forget the background on aptamers. Best of luck on your selection!

Michael Ledbetter said...

Good work. Like Alec said it would be a good idea to describe in more detail the background of your protein. You may want to also add a verbal explanation of the protein pathway in you figure key.

Side Note:
If you are having a lot of trouble with formatting the best ways I have found are to do what Gwen said or to type the text directly into the html tab. You will probably have to simplify you spacing from your original word document.

Arsany Gadallah said...

Nice background information! nice work!

Jeffrey Chang said...

Great idea with a wide range of possible real world applications. Great job!